{"disease":{"id":"ccca-assessed-by-ki67-drop-below-2-7-from-baseline","name":"ccca assessed by ki67 drop below 2 7 from baseline"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06607757","title":"Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"GBG Forschungs GmbH","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}